icon-    folder.gif   Conference Reports for NATAP  
 
  (APASL) 24th Conference of the Asian Pacific
Association for the Study of the Liver
12-15 March, 2014
Brisbane, Australia
Back grey_arrow_rt.gif
 
 
 
Sofosbuvir in Combination With Pegylated Interferon-alfa and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment-Experienced Patients With and Without Compensated Cirrhosis: Results From the LONESTAR-2 Study
 
 
  Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL), March 12-15, 2014, Brisbane, Australia
 
Eric Lawitz,1 Fred F. Poordad,1 Diana M. Brainard,2 Robert H. Hyland,2 Di An,2 William T. Symonds,2 John G. McHutchison,2 Fernando E. Membreno1 1Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX; 2Gilead Sciences, Inc., Foster City, CA, USA

APASL1.gif

APASL2.gif

APASL3.gif

APASL4.gif